ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

March 7, 2014

DCT Board Okays 11 Concept Contract Recompetitions

October 26, 1984

Ethics Commission Say HHS Should Test Injury Compensation

June 18, 1982

In Brief: Oliverio Moves to DEA; Kushner Blass NIH Slow Pay; DeVita Welcomes Hawkin’s Probe

February 6, 1981

Berlin, DeVita Differ On Use Of L-PAM

November 8, 1974

ACS Cancer Control Research Grant Programs Available

May 5, 2000